Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DR26FMDU4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,766
Award facts
- Contract value 100% obligated
- $12,766.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,766.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 tablets of Xtandi 40 mg. The delivery order, issued on October 28, 2025, with an ultimate completion date of October 29, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with recent delivery orders spanning oncology treatments, biologics, vaccines, and specialty pharmaceuticals. The company's underlying IDC with the Defense Logistics Agency, designated as contract SPE2DR and valued at $499,999,999 through December 31, 2036, positions it as a regional prime vendor contractor serving recurring medical supply needs across the global military healthcare system. This Xtandi delivery order represents a routine pharmaceutical procurement supporting the company's established role in fulfilling diverse and specialized pharmaceutical requirements for Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FMDU4?
SPE2DR26FMDU4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DR26FMDU4 worth?
The government has obligated $12,766 on SPE2DR26FMDU4.
Is contract SPE2DR26FMDU4 an order under another contract?
Yes. SPE2DR26FMDU4 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDU4 competed?
The extent of competition for SPE2DR26FMDU4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award